IP Library Patent Application 18743721
Patent Application
App. No. 18/743,721

POLY(OXAZOLINE) CONJUGATES WITH PENDANT CATIONIC GROUPS AND LIPID NANOPARTICLES AND POLYPLEXES INCLUDING SAME

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/743,721
Abstract

Poly(oxazoline) conjugates with pendant cationic groups (cationic POZ) and lipid nanoparticles (LNPs) including cationic POZ used to facilitate delivery of an encapsulated payload. LNPs and polyplexes including cationic POZ and a nucleic acid payload such as, but not limited to, mRNA or modified mRNA are disclosed. Such LNPs have no immunogenicity or reduced immunogenicity as compared to a corresponding LNP containing an ionizable lipid.

Claims (55)

1 . A lipid nanoparticle comprising:

a cationic POZ;

a helper lipid;

a polymer lipid; and

a sterol lipid, wherein the cationic POZ is selected from the group consisting of one cationic POZ of Formulae I-IV:

R-POZ 1 -cation  (I)

wherein R comprises an initiating group and POZ 1 comprises a polyoxazoline polymer;

wherein R comprises an initiating group, n ranges from 1 to 10, R 2 is independently selected for each repeating unit from an unsubstituted or substituted alkyl, alkenyl, aralkyl, heterocyclylalkyl, or active functional group, m ranges from 1 to 100, a is ran, which indicates a random copolymer, or block, which indicates a block copolymer, and T comprises a terminating group;

wherein R comprises an initiating group, n ranges from 1 to 10, R 2 is independently selected for each repeating unit from an unsubstituted or substituted alkyl, alkenyl, aralkyl, heterocyclylalkyl, or active functional group, m ranges from 1 to 100, a is ran, which indicates a random copolymer, or block, which indicates a block copolymer, and T comprises a terminating group; and

wherein R comprises an initiating group, n ranges from 1 to 10, R 2 is independently selected for each repeating unit from an unsubstituted or substituted alkyl, alkenyl, aralkyl, heterocyclylalkyl, or active functional group, m ranges from 1 to 100, a ranges from 3 to 20, and T comprises a terminating group.

2 . The lipid nanoparticle of claim 1 , wherein the lipid nanoparticle comprises about 0.1 percent to about 10 percent cationic POZ, about 30 percent to about 80 percent sterol lipid, about 0.5 percent to about 20 percent polymer lipid, and about 15 percent to about 65 percent helper lipid.

3 . The lipid nanoparticle of claim 2 , wherein the lipid nanoparticle comprises about 35 percent to about 78 percent sterol lipid and about 18 percent to about 63 percent helper lipid.

4 . The lipid nanoparticle of claim 2 , wherein the lipid nanoparticle comprises about 0.3 percent to about 5 percent cationic POZ.

5 . The lipid nanoparticle of claim 1 , wherein the lipid nanoparticle comprises about 30 percent to about 70 percent cationic POZ, about 30 percent to about 50 percent sterol lipid, about 0.5 percent to about 20 percent polymer lipid, and about 5 percent to about 15 percent helper lipid.

6 . The lipid nanoparticle of claim 1 , wherein the polymer lipid is a POZ-lipid of Formula V:

R-POZ 2 -L-Lipid  (V)

wherein R comprises an initiating group,

POZ 2 comprises poly(oxazoline),

L comprises a linking group, and

Lipid comprises a non-charged lipid comprising at least one hydrophobic moiety.

7 . The lipid nanoparticle of claim 6 , wherein the linking group is physiologically degradable.

8 . The lipid nanoparticle of claim 6 , wherein the linking group is stable.

9 . A lipid nanoparticle comprising:

a cationic POZ of Formula I

R-POZ 1 -cation  (I)

wherein R comprises an initiating group and POZ 1 comprises a polyoxazoline polymer;

a helper lipid;

a polymer lipid; and

a sterol lipid.

10 . The lipid nanoparticle of claim 9 , the polymer lipid is a POZ-lipid of Formula V:

R-POZ 2 -L-Lipid  (V)

wherein R comprises an initiating group,

POZ 2 comprises poly(oxazoline),

L comprises a linking group, and

Lipid comprises a non-charged lipid comprising at least one hydrophobic moiety.

11 . The lipid nanoparticle of claim 10 , wherein the linking group is physiologically degradable.

12 . The lipid nanoparticle of claim 10 , wherein the linking group is stable.

13 . The lipid nanoparticle of claim 9 , wherein the lipid nanoparticle comprises about 0.1 percent to about 10 percent cationic POZ, about 30 percent to about 80 percent sterol lipid, about 0.5 percent to about 20 percent polymer lipid, and about 15 percent to about 65 percent helper lipid.

14 . The lipid nanoparticle of claim 9 , wherein the lipid nanoparticle comprises about 30 percent to about 70 percent cationic POZ, about 30 percent to about 50 percent sterol lipid, about 0.5 percent to about 20 percent polymer lipid, and about 5 percent to about 15 percent helper lipid.

15 . A lipid nanoparticle comprising:

a cationic POZ of Formula II

wherein R comprises an initiating group, n ranges from 1 to 10, R 2 is independently selected for each repeating unit from an unsubstituted or substituted alkyl, alkenyl, aralkyl, heterocyclylalkyl, or active functional group, m ranges from 1 to 100, a is ran, which indicates a random copolymer, or block, which indicates a block copolymer, and T comprises a terminating group;

a helper lipid;

a polymer lipid; and

a sterol lipid.

16 . The lipid nanoparticle of claim 15 , the polymer lipid is a POZ-lipid of Formula V:

R-POZ 2 -L-Lipid  (V)

wherein R comprises an initiating group,

POZ 2 comprises poly(oxazoline),

L comprises a linking group, and

Lipid comprises a non-charged lipid comprising at least one hydrophobic moiety.

17 . The lipid nanoparticle of claim 16 , wherein the linking group is physiologically degradable.

18 . The lipid nanoparticle of claim 16 , wherein the linking group is stable.

19 . The lipid nanoparticle of claim 15 , wherein the lipid nanoparticle comprises about 0.1 percent to about 10 percent cationic POZ, about 30 percent to about 80 percent sterol lipid, about 0.5 percent to about 20 percent polymer lipid, and about 15 percent to about 65 percent helper lipid.

20 . The lipid nanoparticle of claim 15 , wherein the lipid nanoparticle comprises about 30 percent to about 70 percent cationic POZ, about 30 percent to about 50 percent sterol lipid, about 0.5 percent to about 20 percent polymer lipid, and about 5 percent to about 15 percent helper lipid.

Assignments (3)
CHANGE OF NAME Recorded Aug 12, 2024
From: SERINA THERAPEUTICS, INC.
To: SERINA THERAPEUTICS (AL), INC.
Reel/Frame 068246/0584 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2024
From: KIM, WOOKHYUN; SMITH, KELLEY
To: SERINA THERAPEUTICS (AL), INC.
Reel/Frame 067786/0940 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2024
From: MOREADITH, RANDALL; HARRIS, J MILTON; VIEGAS, TACEY; YOON, KUNSANG; FANG, ZHIHAO; WEIMER, REBECCA
To: SERINA THERAPEUTICS, INC.
Reel/Frame 067755/0675 →